Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abilify Maintena versus other long-acting injectable antipsychotics in schizophrenia
ACTRN12617000211369Phase 4Completed
- Sponsor
- Dr. Benjamin Hadikusumo
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole, risperidone, olanzapine, paliperidone, fluphenazine and 2 more in schizophrenia, sponsored by Dr. Benjamin Hadikusumo. Primary endpoint: Change in quality of life measured by Quality of Life Scale. Started Apr 2017; status: completed.
02
Drugs
aripiprazolerisperidoneolanzapinepaliperidonefluphenazine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ACTRN12617000211369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000211369.